Premium
Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease
Author(s) -
Lee K. K. C.,
You J. H. S.,
Ho J. T. S.,
Suen B. Y.,
Yung M. Y.,
Lau W. H.,
Lee V. W. Y.,
Sung J. Y.,
Chan F. K. L.
Publication year - 2003
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2003.01680.x
Subject(s) - omeprazole , celecoxib , medicine , diclofenac , gastroenterology , arthritis , surgery , anesthesia
Summary Aim : To evaluate the economic impact of celecoxib therapy vs. diclofenac plus omeprazole therapy for the treatment of arthritis in Chinese patients with a high risk of bleeding, from the perspective of a public health organization in Hong Kong. Methods : The medical records of 287 Chinese arthritic patients with a history of bleeding ulcers who had previously participated in a randomised study of celecoxib 200 mg twice daily and extended‐release diclofenac 75 mg twice daily plus 20 mg of omeprazole daily for 6 months were reviewed. Results : Compared to the diclofenac plus omeprazole group, the average total direct cost per patient in the celecoxib group showed a significant reduction of 11%, from $HK 10 915 (range $HK 10 915–57 899) to $HK 9714 (range $HK 9714–89 770) ( P < 0.0001) (1 $US = 7.8 $HK). The median direct medical cost for routine management in the celecoxib group was significantly lower (11%) than that for the diclofenac plus omeprazole group [$HK 10 915 (range 10 915–28 048) vs. $HK 9714 (range $HK 6946–26 179) ( P < 0.0001)]. In patients who experienced recurrent bleeding, the celecoxib group showed a significantly higher median cost of management of recurrent bleeding than the diclofenac plus omeprazole group [$HK 8466 (range 572–29 851) vs. $HK 23 210 (range $HK 12 318–65 823)] ( P = 0.036). Conclusions : Celecoxib therapy appears to cost less compared with diclofenac plus omeprazole for treatment of arthritis in Chinese patients with a high risk of bleeding.